| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02318563 Details | 2018-01-04 Interventional | 3 | 0 | Cannabidiol Pharmaceutical … Epilepsies, Myo… Syndrome Dravet Syndrome | Sponsor elected not to continue with study. - | |||
| NCT02318537 Details | 2018-01-04 Interventional | 3 | 0 | Cannabidiol Pharmaceutical … Lennox Gastaut … Syndrome Lennox-Gastaut … | Sponsor elected not to continue with study. - | |||
| NCT02138409 Details | 2018-01-04 Interventional | 3 | 0 | Fentanyl Chronic Pain | Sponsor elected not to continue with study. - | |||
| NCT00369070 Details | 2018-01-04 Interventional | 2 | 186 | Bevacizumab Carboplatin Imetelstat Motesanib dipho… Paclitaxel Carcinoma, Non-… Advanced Non-sq… | - - | |||
| NCT02697851 Details | 2018-01-02 Interventional | 1 | 13 | Atazanavir Sulf… Cobicistat Ethinyl Estradi… Ethinyl Estradi… Ethinyl estradi… Levonorgestrel HIV | Insufficient enrolment and "business reasons" - | |||
| NCT01061671 Details | 2018-01-02 Interventional | 3 | 885 | Simvastatin Lung Diseases Pulmonary Disea… | Futility Early termination by the Data and Safety Monitoring Board due to futility in respect to a treatment effect. The original study population goal was 1200 and the study was terminated at 885 participants. | |||
| NCT02993991 Details | 2017-12-29 Interventional | 1 | 0 | Durvalumab Mocetinostat Carcinoma Carcinoma, Squa… Squamous Cell C… Resectable Squa… Squamous Cell C… Squamous Cell C… | The study has been terminated due to a change in internal prioritization and not due to any
safety concerns. - | |||
| NCT02701517 Details | 2017-12-29 Interventional | 2 | - | Alemtuzumab Cyclosporine Cyclosporins Methotrexate Neoplasms Unrecognized Co… | The trial was stopped before the targeted number of patients was reached due to lack of
support. - | |||
| NCT01800162 Details | 2017-12-29 Interventional | 1/2 | 2 | Methotrexate Cardiac Complex… Pregnancy, Ecto… Ectopic Pregnan… Persistent Preg… | A new protocol was written to replace this protocol. - | |||
| NCT01332617 Details | 2017-12-29 Interventional | 2 | 0 | Bendamustine Hy… Bortezomib Diclofenac Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Simvastatin Zoledronic Acid Multiple Myelom… Neoplasms, Plas… Myeloma | Investigators no longer interested in activating study - | |||
| NCT01938833 Details | 2017-12-28 Interventional | 1/2 | 9 | Albumin-Bound P… Paclitaxel Romidepsin Breast Neoplasm… Breast Neoplasm… Inflammatory Br… HER2-negative B… Inflammatory Br… Male Breast Can… Recurrent Breas… Stage IV Breast… | Closed by Sponsor - | |||
| NCT00871689 Details | 2017-12-28 Interventional | 2 | 2 | Aldesleukin Cyclophosphamid… Fludarabine Fludarabine pho… Interleukin-2 Leukemia | Due to graft failure. Quantitative, phenotypic and functional assessment of the in vivo expanded UCB-derived NK cells on Day 72 were not performed. Patients were not well enough to provide research samples. | |||
| NCT00790296 Details | 2017-12-28 Interventional | 2 | 11 | Hormones Thyrotropin-Rel… Fatigue Cancer-related … | Interim analyses showed statistically and clinically significant results. Limitation: small sample size | |||
| NCT00668564 Details | 2017-12-28 Interventional | 2 | 18 | Alemtuzumab Busulfan Cyclophosphamid… Aphasia, Primar… Aspartylglucosa… Frontotemporal … Fucosidosis Leukodystrophy,… Mannosidase Def… Metabolism, Inb… Mucopolysacchar… Mucopolysacchar… Mucopolysacchar… Niemann-Pick Di… Niemann-Pick Di… Niemann-Pick Di… Niemann-Pick Di… Pick Disease of… Sphingolipidose… Syndrome Wolman Disease alpha-Mannosido… Alpha Mannosido… Hurler's Syndro… Krabbe Disease Maroteaux-Lamy … Niemann-Pick Di… Sly Syndrome Wolman's Diseas… | Replaced by another study Other secondary objectives outlined in study protocol were not analyzed; number of patients were too few to be relevant. | |||
| NCT00625729 Details | 2017-12-28 Interventional | 1/2 | 6 | Aldesleukin Cyclophosphamid… Fludarabine Fludarabine pho… Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, Non-H… | No patients exhibited natural killer cell expansion (primary endpoint). Study was terminated early due to lack of NK expansion and failure to meet primary outcome. | |||
| NCT00617929 Details | 2017-12-28 Interventional | 2 | 12 | Antilymphocyte … Clofarabine Rituximab Thymoglobulin Cancer | Replaced by another protocol - | |||
| NCT00392782 Details | 2017-12-28 Interventional | 2 | 24 | Antilymphocyte … Fludarabine Fludarabine pho… Thiotepa Leukemia Myelodysplastic… Preleukemia Syndrome | - - | |||
| NCT00354172 Details | 2017-12-28 Interventional | 2 | 16 | Aldesleukin Cyclophosphamid… Cyclosporine Cyclosporins Fludarabine Fludarabine pho… Interleukin-2 Lenograstim Methylprednisol… Methylprednisol… Methylprednisol… Mycophenolic Ac… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Leukemia Myelodysplastic… Preleukemia Syndrome | Competing study was started. - | |||
| NCT00352118 Details | 2017-12-28 Interventional | 2 | 4 | Docetaxel Fluorouracil Lenograstim Head and Neck N… Head and Neck C… | Low dose radiation treatment was not appropriate for these patients. All 4 patients received high dose radiation (66-70 Gy). The radiation oncologist on this study deemed low dose radiation treatment was not appropriate for these patients. Therefore, the study participants are not evaluable. | |||
| NCT01803711 Details | 2017-12-27 Interventional | 2/3 | 6 | Desvenlafaxine … Cardiovascular … Depression Depressive Diso… Cancer Diabetes Major Depressio… | Lack of recruitment and no resources Due to very low enrollment in both arms, only descriptive analyses was completed for both arms |